CJC-1295 Pharmacy A pharmacy dossier · CJC-1295

§ N° VI · References

CJC-1295 References and Citations

Every quantitative claim in the dossier maps to a numbered citation here — Phase I trial, foundational receptor pharmacology, regulatory briefings, and the broader GHRH-analog class literature.

Fig N° VI · Citation ledger

Cartesian editorial diagram of a quiet citation ledger — fifteen thin vertical ink hairlines with three taller marks indicating primary-source citations
The CJC-1295 published canon, rendered as a quiet shelf of journal-spine indices.

§ N° I

Reference table

The CJC-1295 references and citations on this page constitute the full source set for the dossier. Nineteen entries: the foundational Phase I human dose-escalation trial (Teichman 2006), the GHRH-receptor mechanism papers (Jetté 2005, Alba 2006, Frohman 1995, Zhou 2020, the 2025 GHRHR review), the ipamorelin and GH-secretagogue characterization (Raun 1998, Ishida 2020), the tesamorelin class comparator (Falutz 2007, Stanley 2014), the modified GRF (1-29) chemistry reference, the ConjuChem Phase II halt reporting, the FDA Pharmacy Compounding Advisory Committee briefing, the FDA 503A bulks-list action coverage, the WADA Prohibited List 2026, the long-term GH-treatment safety analysis (Johannsson 2022), and the historical sermorelin pharmacology reference (Frohman 1995). DOIs and PubMed identifiers are listed where available; URLs link to the canonical archive.

All citations are organized by section below in canonical order — peer-reviewed primary research, peer-reviewed reviews, regulatory documentation, and historical / class-context references. Citations marked with PMID or DOI are direct links to the public PubMed or publisher archive.

Table N° II · Full citation list

# Citation Year
1 Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805.PMID 16352683 · DOI 10.1210/jc.2005-1536 · link 2006
2 Teichman SL, et al. CJC-1295 Phase I pharmacokinetics — half-life and IGF-1 elevation duration data. J Clin Endocrinol Metab. 2006;91(3):799-805.PMID 16352683 · DOI 10.1210/jc.2005-1536 · link 2006
3 Jetté L, Léger R, Thibaudeau K, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058.PMID 15817669 · DOI 10.1210/en.2004-1286 · link 2005
4 Jetté L, et al. CJC-1295 albumin-conjugation pharmacokinetics in rats — peptide detectable in plasma beyond 72 hours, 4-fold GH AUC over unmodified GRF. Endocrinology. 2005;146(7):3052-3058.PMID 15817669 · DOI 10.1210/en.2004-1286 · link 2005
5 Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E1294.PMID 16822960 · DOI 10.1152/ajpendo.00201.2006 · link 2006
6 Teichman SL, et al. Safety and tolerability of CJC-1295 in Phase I dose escalation — no serious adverse reactions; injection-site reactions and transient flushing reported. J Clin Endocrinol Metab. 2006;91(3):799-805.PMID 16352683 · DOI 10.1210/jc.2005-1536 · link 2006
7 Growth hormone-releasing hormone receptor (GHRH-R) and its signaling (review). Rev Endocr Metab Disord. 2025.PMID PMC12137518 · DOI 10.1007/s11154-025-09952-x · link 2025
8 Zhou F, Zhang H, Cong Z, Zhao LH, et al. Structural basis for activation of the growth hormone-releasing hormone receptor. Nat Commun. 2020;11(1):5205.DOI 10.1038/s41467-020-18945-0 · link 2020
9 Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561.PMID 9849822 · DOI 10.1530/eje.0.1390552 · link 1998
10 Ishida J, Saitoh M, Ebner N, Springer J, Anker SD, von Haehling S. Growth hormone secretagogues: history, mechanism of action, and clinical development. JCSM Rapid Communications. 2020;3(1):25-37.DOI 10.1002/rco2.9 · link 2020
11 Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-2370.PMID 18046029 · DOI 10.1056/NEJMoa072375 · link 2007
12 Modified GRF (1-29) — chemistry and pharmacology overview (review compendium, citing primary GRF analog literature).link
13 Aidsmap editorial. Lipodystrophy study halted after patient death (news report on ConjuChem Phase II CJC-1295 trial). aidsmap.com. 2006.link 2006
14 U.S. Food and Drug Administration. FDA Briefing Document — Pharmacy Compounding Advisory Committee (PCAC) Meeting on peptide bulk drug substances. 2024.link 2024
15 World Anti-Doping Agency. The Prohibited List — International Standard (Section S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics). WADA Prohibited List 2026.link 2026
16 Johannsson G, Touraine P, Feldt-Rasmussen U, et al. Long-term safety of growth hormone in adults with growth hormone deficiency: overview of 15,809 GH-treated patients. J Clin Endocrinol Metab. 2022.PMID PMC9202689 · DOI 10.1210/clinem/dgac199 · link 2022
17 Lexology editorial. FDA removes certain peptide bulk drug substances from Category 2 of interim 503A bulks list and sets dates for PCAC review. 2024.link 2024
18 Stanley TL, Feldpausch MN, Oh J, Branch KL, Lee H, Torriani M, Grinspoon SK. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312(4):380-389.DOI 10.1001/jama.2014.8334 · link 2014
19 Frohman LA, Kineman RD. Growth hormone-releasing hormone: synthesis and signaling. Recent Prog Horm Res. 1995;50:65-110.PMID 7740167 · link 1995
  1. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. ↗PMID 16352683 · DOI 10.1210/jc.2005-1536
  2. Teichman SL, et al. CJC-1295 Phase I pharmacokinetics — half-life and IGF-1 elevation duration data. J Clin Endocrinol Metab. 2006;91(3):799-805. ↗PMID 16352683 · DOI 10.1210/jc.2005-1536
  3. Jetté L, Léger R, Thibaudeau K, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. ↗PMID 15817669 · DOI 10.1210/en.2004-1286
  4. Jetté L, et al. CJC-1295 albumin-conjugation pharmacokinetics in rats — peptide detectable in plasma beyond 72 hours, 4-fold GH AUC over unmodified GRF. Endocrinology. 2005;146(7):3052-3058. ↗PMID 15817669 · DOI 10.1210/en.2004-1286
  5. Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E1294. ↗PMID 16822960 · DOI 10.1152/ajpendo.00201.2006
  6. Teichman SL, et al. Safety and tolerability of CJC-1295 in Phase I dose escalation — no serious adverse reactions; injection-site reactions and transient flushing reported. J Clin Endocrinol Metab. 2006;91(3):799-805. ↗PMID 16352683 · DOI 10.1210/jc.2005-1536
  7. Growth hormone-releasing hormone receptor (GHRH-R) and its signaling (review). Rev Endocr Metab Disord. 2025. ↗PMID PMC12137518 · DOI 10.1007/s11154-025-09952-x
  8. Zhou F, Zhang H, Cong Z, Zhao LH, et al. Structural basis for activation of the growth hormone-releasing hormone receptor. Nat Commun. 2020;11(1):5205. ↗DOI 10.1038/s41467-020-18945-0
  9. Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. ↗PMID 9849822 · DOI 10.1530/eje.0.1390552
  10. Ishida J, Saitoh M, Ebner N, Springer J, Anker SD, von Haehling S. Growth hormone secretagogues: history, mechanism of action, and clinical development. JCSM Rapid Communications. 2020;3(1):25-37. ↗DOI 10.1002/rco2.9
  11. Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-2370. ↗PMID 18046029 · DOI 10.1056/NEJMoa072375
  12. Modified GRF (1-29) — chemistry and pharmacology overview (review compendium, citing primary GRF analog literature). ↗
  13. Aidsmap editorial. Lipodystrophy study halted after patient death (news report on ConjuChem Phase II CJC-1295 trial). aidsmap.com. 2006. ↗
  14. U.S. Food and Drug Administration. FDA Briefing Document — Pharmacy Compounding Advisory Committee (PCAC) Meeting on peptide bulk drug substances. 2024. ↗
  15. World Anti-Doping Agency. The Prohibited List — International Standard (Section S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics). WADA Prohibited List 2026. ↗
  16. Johannsson G, Touraine P, Feldt-Rasmussen U, et al. Long-term safety of growth hormone in adults with growth hormone deficiency: overview of 15,809 GH-treated patients. J Clin Endocrinol Metab. 2022. ↗PMID PMC9202689 · DOI 10.1210/clinem/dgac199
  17. Lexology editorial. FDA removes certain peptide bulk drug substances from Category 2 of interim 503A bulks list and sets dates for PCAC review. 2024. ↗
  18. Stanley TL, Feldpausch MN, Oh J, Branch KL, Lee H, Torriani M, Grinspoon SK. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312(4):380-389. ↗DOI 10.1001/jama.2014.8334
  19. Frohman LA, Kineman RD. Growth hormone-releasing hormone: synthesis and signaling. Recent Prog Horm Res. 1995;50:65-110. ↗PMID 7740167